Skip to main content

Advertisement

SpringerLink
Log in

The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma

  • Melanoma
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

In-transit melanoma represents a distinct disease pattern in which melanoma recurs as dermal or subcutaneous nodules between the primary melanoma site and the draining regional lymph node basin. The disease pattern is often not amenable to complete surgical resection. Since the 1950s, regional therapies have been explored for the treatment of this disease entity, with the goal of maximizing delivery of the therapeutic agent to the tumor while minimizing systemic toxicity. We reviewed landmark studies describing and evaluating regional chemotherapy and intralesional therapies for patients with in-transit melanoma metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12:587–596

    PubMed  Google Scholar 

  2. Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol. 2005;23:4588–4590

    PubMed  Google Scholar 

  3. Read RL, Haydu L, Saw RP, et al. In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol. 2015;22:475–481

    PubMed  Google Scholar 

  4. Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7:87–97

    CAS  PubMed  Google Scholar 

  5. Creech O Jr Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616–632.

    PubMed  PubMed Central  Google Scholar 

  6. Creech O Jr, Krementz ET, Ryan RF, Reemtsma K, Winblad JN. Experiences with isolation-perfusion technics in the treatment of cancer. Ann Surg. 1959;149:627–640

    PubMed  PubMed Central  Google Scholar 

  7. Creech O Jr, Ryan RF, Krementz ET. Treatment of melanoma by isolation-perfusion technique. J Am Med Assoc. 1959;169:339–343

    PubMed  Google Scholar 

  8. Klopp CT, Alford TC, Bateman J, Berry GN, Winship T. Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report. Ann Surg. 1950;132:811–832.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Krementz ET, Ryan RF: Chemotherapy of melanoma of the extremities by perfusion: fourteen years clinical experience. Ann Surg. 1972;175:900–917

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol. 1998;16:2906–2912

    CAS  PubMed  Google Scholar 

  11. Lienard D, Eggermont AM, Kroon BB, Schraffordt Koops H, Lejeune FJ: Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol. 1998;14:202–209

    CAS  PubMed  Google Scholar 

  12. Vrouenraets BC, Nieweg OE, Kroon BB. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg. 1996;83:1319-28

    CAS  PubMed  Google Scholar 

  13. Taber SW, Polk HC Jr. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Ann Surg Oncol. 1997;4:440–445

    CAS  PubMed  Google Scholar 

  14. Fraker DL. Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg. 1999;36:841–907

    CAS  PubMed  Google Scholar 

  15. Bates DA, Mackillop WJ. The effect of hyperthermia in combination with melphalan on drug-sensitive and drug-resistant CHO cells in vitro. Br J Cancer. 1990;62:183–188

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Laskowitz DT, Elion GB, Dewhirst MW, Griffith OW, Savina PM, Blum MR, et al. Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft. Radiat Res. 1992;129:218–223

    CAS  PubMed  Google Scholar 

  17. Aloia TA, Grubbs E, Onaitis M, Mosca PJ, Cheng TY, Seigler H, et al. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch Surg. 2005;140:1115–1120

    PubMed  Google Scholar 

  18. Barbour AP, Thomas J, Suffolk J, Beller E, Smithers BM. Isolated limb infusion for malignant melanoma: predictors of response and outcome. Ann Surg Oncol. 2009;16:3463–3472

    PubMed  Google Scholar 

  19. Nieweg OE, Kroon BB. Isolated limb perfusion with melphalan for melanoma. J Surg Oncol. 2014;109:332–337

    PubMed  Google Scholar 

  20. Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L, Villegas-Portero R, Nieto-Garcia A. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist. 2010;15:416–427

    PubMed  PubMed Central  Google Scholar 

  21. Alexander HR Jr, Fraker DL, Bartlett DL, Libutti SK, Steinberg SM, Soriano P, et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol. 2010;28:114–118

    PubMed  Google Scholar 

  22. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, for members of the American Joint Committee on Cancer Melanoma Expert P, the International Melanoma Database and Discovery Platform, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–492

    PubMed  PubMed Central  Google Scholar 

  23. Chin-Lenn L, Temple-Oberle C, McKinnon JG. Isolated limb infusion: efficacy, toxicity and an evolution in the management of in-transit melanoma. Plast Surg (Oakv). 2015;23:25–30

    PubMed  PubMed Central  Google Scholar 

  24. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905–910

    CAS  PubMed  Google Scholar 

  25. Raymond AK, Beasley GM, Broadwater G, Augustine CK, Padussis JC, Turley R, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg. 2011;213:306–316

    PubMed  PubMed Central  Google Scholar 

  26. Reintgen DS, Cruse CW, Wells KE, Saba HI, Slingluff CL Jr. Isolated limb perfusion for recurrent melanoma of the extremity. Ann Plast Surg. 1992;28:50–54

    CAS  PubMed  Google Scholar 

  27. Papa MZ, Klein E, Karni T, Koller M, Davidson B, Azizi E, et al. Regional hyperthermic perfusion with cisplatin following surgery for malignant melanoma of the extremities. Am J Surg. 1996;171:416–420

    CAS  PubMed  Google Scholar 

  28. Lienard D, Eggermont AM, Schraffordt Koops H, Kroon BB, Rosenkaimer F, Autier P,et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res. 1994;4 Suppl 1:21–26

    PubMed  Google Scholar 

  29. Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006;24:4196–4201

    CAS  PubMed  Google Scholar 

  30. Hoekstra HJ, Veerman K, van Ginkel RJ. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion? J Surg Oncol. 2014;109:338–347

    CAS  PubMed  Google Scholar 

  31. Olofsson R, Mattsson J, Lindner P. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma. Int J Hyperthermia. 2013;29:551–557

    CAS  PubMed  Google Scholar 

  32. Thompson JF, Waugh RC, Saw RPM, Kam PCA. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Regional Cancer Treat. 1994;7:188–192

    Google Scholar 

  33. Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol. 2002;9:127–136

    PubMed  Google Scholar 

  34. Beasley GM, Petersen RP, Yoo J, McMahon N, Aloia T, Petros W, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15:2195–205

    PubMed  Google Scholar 

  35. O’Donoghue C, Perez MC, Mullinax JE, Hardman D, Sileno S, Naqvi SMH, et al. Isolated limb infusion: a single-center experience with over 200 infusions. Ann Surg Oncol. 2017;24:3842–3849

    PubMed  Google Scholar 

  36. Miura JT, Kroon HM, Beasley GM, Mullen D, Farrow NE, Mosca PJ, et al. Long-term oncologic outcomes after isolated limb infusion for locoregionally metastatic melanoma: an international multicenter analysis. Ann Surg Oncol. 2019;26(8):2486–2494

    PubMed  Google Scholar 

  37. Dossett LA, Ben-Shabat I, Olofsson Bagge R, Zager JS. Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma. Ann Surg Oncol. 2016;23:2330–2335

    PubMed  Google Scholar 

  38. Kroon HM, Thompson JF. Isolated limb infusion and isolated limb perfusion for melanoma: can the outcomes of these procedures be compared? Ann Surg Oncol. 2019;26:8–9

    PubMed  Google Scholar 

  39. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–1355

    CAS  PubMed  Google Scholar 

  40. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877–1888

    PubMed  Google Scholar 

  41. Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D. Immunotherapy in melanoma: recent advances and future directions. Eur J Surg Oncol. 2017;43:604–611

    CAS  PubMed  Google Scholar 

  42. Byers BA, Temple-Oberle CF, Hurdle V, McKinnon JG. Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review. J Surg Oncol. 2014;110:770–775

    CAS  PubMed  Google Scholar 

  43. Krone B, Kolmel KF, Henz BM, Grange JM. Protection against melanoma by vaccination with Bacille Calmette-Guerin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. Eur J Cancer. 2005;41:104–117

    CAS  PubMed  Google Scholar 

  44. Danielli R, Patuzzo R, Di Giacomo AM, Gallino G, Maurichi A, Di Florio A, et al. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother. 2015;64:999–1009

    CAS  PubMed  Google Scholar 

  45. Sato-Kaneko F, Yao S, Ahmadi A, Zhang SS, Hosoya T, Kaneda MM, et al. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017;2(18):e93397

    PubMed Central  Google Scholar 

  46. Kolmel KF, Grange JM, Krone B, Mastrangelo G, Rossi CR, Henz BM, et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer. 2005;41:118–125

    CAS  PubMed  Google Scholar 

  47. Ross MI. Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma. J Surg Oncol. 2014;109:314–319

    PubMed  Google Scholar 

  48. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;6:226ra32

    PubMed  PubMed Central  Google Scholar 

  49. Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, et al. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci Transl Med. 2017;9(408):eaan4220

    PubMed  PubMed Central  Google Scholar 

  50. Kuryk L, Moller AW, Jaderberg M. Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. Oncoimmunology. 2019;8:e1532763

    PubMed  Google Scholar 

  51. Shi SW, Li B, Dong Y, Ge Y, Qu X, Lu LG, et al. In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for malignant melanoma. Hum Gene Ther Clin Dev. 2019;30(1):7–18

    CAS  PubMed  Google Scholar 

  52. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642–662

    CAS  PubMed  Google Scholar 

  53. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27:5763–5771

    CAS  PubMed  Google Scholar 

  54. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–2788

    CAS  Google Scholar 

  55. Veverka KK, Jakub JW, Baum CL. Responses to topical diphenylcyclopropenone as an adjunct treatment for in-transit melanoma: a tertiary referral center experience. Dermatol Surg. 2018;44:1501–1508

    CAS  PubMed  Google Scholar 

  56. Gibbons IL, Sonagli M, Bertolli E, Macedo MP, Pinto CAL, Duprat Neto JP. Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience. An Bras Dermatol. 2018;93:299–301

    PubMed  Google Scholar 

  57. Read T, Webber S, Tan J, Wagels M, Schaider H, Soyer HP, et al. Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases: results of a prospective, non-randomized, single-centre study. J Eur Acad Dermatol Venereol. 2017;31:2030–2037

    CAS  PubMed  Google Scholar 

  58. Damian DL, Saw RP, Thompson JF. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. J Surg Oncol. 2014;109:308–313

    CAS  PubMed  Google Scholar 

  59. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Metric Study Group. et al.; Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–114

    CAS  PubMed  Google Scholar 

  60. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17:1558–1568

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Jaques DP, Coit DG, Brennan MF. Major amputation for advanced malignant melanoma. Surg Gynecol Obstet. 1989;169:1–6

    CAS  PubMed  Google Scholar 

  62. Ebskov LB. Major amputation for malignant melanoma: an epidemiological study. J Surg Oncol. 1993;52:89–91

    CAS  PubMed  Google Scholar 

  63. Harrington KJ, Andtbacka RH, Collichio F, Downey G, Chen L, Szabo Z, et al. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. Onco Targets Ther. 2016;9:7081–7093

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Jiang BS, Speicher PJ, Thomas S, Mosca PJ, Abernethy AP, Tyler DS. Quality of life after isolated limb infusion for in-transit melanoma of the extremity. Ann Surg Oncol. 2015;22:1694–700

    PubMed  Google Scholar 

  65. Weitman ES, Perez M, Thompson JF, Andtbacka RHI, Dalton J, Martin ML, et al. Quality of life patient-reported outcomes for locally advanced cutaneous melanoma. Melanoma Res. 2018;28:134–142

    PubMed  Google Scholar 

  66. Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, et al. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol Res. 2018;6(2):189–200

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170:1109–1119.e10

    Google Scholar 

  68. Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34:2619–2626

    CAS  PubMed  Google Scholar 

  69. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36:1658–1667

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Duke University, Durham, NC, USA

    Georgia M. Beasley MD

  2. Duke University Medical Center, Durham, NC, USA

    Georgia M. Beasley MD

  3. Department of Cutaneous Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA

    Jonathan S. Zager MD

  4. Department of Surgery, University of South Florida Morsani School of Medicine, Tampa, FL, USA

    Jonathan S. Zager MD

  5. Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia

    John F. Thompson MD

  6. Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia

    John F. Thompson MD

  7. Discipline of Surgery, The University of Sydney, Sydney, NSW, Australia

    John F. Thompson MD

Authors
  1. Georgia M. Beasley MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan S. Zager MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John F. Thompson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georgia M. Beasley MD.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beasley, G.M., Zager, J.S. & Thompson, J.F. The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma. Ann Surg Oncol 27, 35–42 (2020). https://doi.org/10.1245/s10434-019-07760-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-019-07760-7

Search

Navigation